
United Therapeutics (UTHR) Stock Forecast & Price Target
United Therapeutics (UTHR) Analyst Ratings
Bulls say
United Therapeutics is well-positioned to become part of the standard of care for IPF patients as its recent TETON-1 data showed clinically meaningful preservation of FVC, improved patient symptoms and quality of life, and support for both mono and combination therapy use. With a significant opportunity in the IPF market and expected peak revenue of $5B from Tyvaso, the company has a strong financial outlook. Additionally, United is developing new delivery methods for its treatments to improve tolerability and is following a disciplined spending approach to support future launches and studies.
Bears say
United Therapeutics is currently generating stable but not exceptional revenues from its PAH franchise, and is highly dependent on the success of its treprostinil-based drugs. However, there are potential risks to these drugs achieving peak commercial revenue, such as market size, penetration rates, and generic erosion. Additionally, the company's operating expenses may not see significant decreases without additional business development. While the positive TETON-2 results for the use of Tyvaso in IPF increase the chances of success for TETON-1 and the FDA's new single pivotal trial policy may provide some protection, it is uncertain if these will be enough to significantly drive growth for the company in the near future.
This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
United Therapeutics (UTHR) Analyst Forecast & Price Prediction
Start investing in United Therapeutics (UTHR)
Order type
Buy in
Order amount
Est. shares
0 shares